A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Chronic heart failure
- Focus Pharmacokinetics
- Sponsors Amgen
- 02 Aug 2017 Results published in a Cytokinetics media release.
- 15 May 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2017 According to a Cytokinetics media release, data from the study is expected in the third quarter of 2017.